SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 25, 2003
SALIX PHARMACEUTICALS, LTD.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
| 000-23265 | 94-3267443 | |
| (Commission file Number) | (IRS Employer ID Number) |
| 8540 Colonnade Center Drive, Suite 501, Raleigh, North Carolina 27615 |
| (Address of principal executive offices) (Zip Code) |
Registrant’s telephone number, including area code(919) 862-1000
|
Item 5. Other Events and Regulation FD Disclosure
On November 25, 2003, Salix Pharmaceuticals, Ltd. (the “Registrant”) issued a press release announcing that the Registrant has submitted an amendment to its New Drug Application (NDA) for Rifaximin to the U.S. Food and Drug Administration (FDA) in response to the FDA approvable letter of October 25, 2002. A copy of this press release is attached.
Item 7. Financial Statements and Exhibits.
| (c) | Exhibits |
Exhibit | Description | |
99.1 | Press release dated November 25, 2003, announcing that the Registrant has submitted an amendment to its NDA for Rifaximin to the FDA in response to the FDA approvable letter of October 25, 2002. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 25, 2003 | SALIX PHARMACEUTICALS, LTD.
By: /s/ Adam C. Derbyshire Adam C. Derbyshire Senior Vice President and Chief Financial Officer |
